Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials

INTRODUCTION: Myasthenia gravis (MG), a rare neuromuscular disease, is often initially treated using acetylcholinesterase inhibitors. Patients who do not respond adequately depend on the use of corticosteroids or other immunosuppressive medication, but these may have serious side effects. Clinical o...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrinten, Charlotte, Lipka, Alexander F, van Zwet, Erik W, Schimmel, Kirsten J M, Cornel, Martina C, Kuijpers, Marja R, Hekster, Yechiel A, Weinreich, Stephanie S, Verschuuren, Jan J G M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513481/
https://www.ncbi.nlm.nih.gov/pubmed/26185179
http://dx.doi.org/10.1136/bmjopen-2015-007863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513481/
https://www.ncbi.nlm.nih.gov/pubmed/26185179
http://dx.doi.org/10.1136/bmjopen-2015-007863

Ejemplares similares